Evidence-based biosafety: A review of the principles and effectiveness of microbiological containment measures

Clinical Microbiology Reviews

Volumn 21, Issue 3, 2008, Pages 403-425

  Kimman, Tjeerd G ^a   Smit, Eric ^a   Klein, Michèl R ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL STRAIN; BIOSAFETY; CLINICAL EVALUATION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; EXPERIMENTAL STUDY; HAZARDOUS WASTE; MICROBIOLOGY; MICROORGANISM; OBSERVATIONAL STUDY; REVIEW; RISK ASSESSMENT;

CONTAINMENT OF BIOHAZARDS; HUMANS; LABORATORIES; MEDICAL WASTE; RISK ASSESSMENT; SAFETY;

EID: 47949124721     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.00014-08     Document Type: Review

References (161)

1. Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656-662.
2. Angelakopoulos, H., K. Loock, D. M. Sisul, E. R. Jensen, J. F. Miller, and E. L. Hohmann. 2002. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70:3592-3601.
3. Anonymous. 2004. Ebola virus, laboratory accident - USA (Maryland). ProMED-mail, 2 February 2004. 20040220.0550. http://www.promedmail. org. Accessed 22 September 2007.
4. Anonymous. 2004. Ebola, lab accident death - Russia (Siberia). ProMED-mail, 22 May 2004. 20040522.1377. http://www.promedmail.org. Accessed 22 September 2007.
5. Bałazy, A. M., Toivola, A. Adhikari, S. K. Sivasubramani, T. Reponen, and S. A. Grinshpun. 2006. Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? Am. J. Infect. Control 34:51-57.
6. Barbeito, M. S., and L. A. Taylor. 1968. Containment of microbial aerosols in a microbiological safety cabinet. Appl. Microbiol. 16:1225-1229.
7. Barbeito, M. S., and E. A. Brookey, Jr. 1976. Microbiological hazard from the exhaust of a high-vacuum sterilizer. Appl. Environ. Microbiol. 32:671-678.
8. Barry, M., M. Russi, L. Armstrong, D. Geller, R. Tesh, L. Dembry, J. P. Gonzalez, A. S. Khan, and C. J. Peters. 1995. Treatment of a laboratory-acquired Sabia virus infection. N. Engl. J. Med. 333:294-296.
9. Berg, P., D. Baltimore, S. Brenner, R. O. Roblin III, and M. F. Singer. 1975. Asilomar conference on recombinant DNA molecules. Science 188:991-994.
10. Borchert, M. 2001. Marburg hemorrhagic fever, 1967 to the present (02). ProMED-mail, 8 Feb 2001. 20010208.0248. ]http://www.promedmail.org. Accessed 22 September 2007.
11. 1. Boutet, R., J. M. Stuart, E. B. Kaczmarski, S. J. Gray, D. M. Jones, and N. Andrews. 2001. Risk of laboratory-acquired meningococcal disease. J. Hosp. Infect. 49:282-284.
12. Bouza, E., C. Sanchez-Carrillo, S. Hernangomez, M. J. Gonzalez, et al. 2005. Laboratory-acquired brucellosis: a Spanish national survey. J. Hosp. Infect. 61:80-83.
13. Braat, H., P. Rottiers, D. W. Hommes, N. Huyghebaert, E. Remaut, J. P. Remon, S. J. van Deventer, S. Neirynck, M. P. Peppelenbosch, and L. Steidler. 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4:754-759.
14. Breban, R., R. Vardavas, and S. Blower. 2007. Theory versus data: how to calculate R0? PLoS One 2:e282.
15. Reference deleted.
16. Buesching, W. J., J. C. Neff, and H. M. Sharma. 1989. Infectious hazards in the clinical laboratory: a program to protect laboratory personnel. Clin. Lab. Med. 9:351-361.
17. Bukovsky, A. A., J. P. Song, and L. Naldini. 1999. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73:7087-7092.
18. Casadevall, A., and L. A. Pirofski. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67:3703-3713.
19. CDC. 1974. Classification of etiological agents on the basis of hazard. U.S. Public Health Service, Washington, DC.
20. CDC. 2001. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb. Mortal. Wkly. Rep. 50:1-25.
21. CDC. 2002. Laboratory-acquired meningococcal disease - United States, 2000. Morb. Mortal. Wkly. Rep. 51:141-144.
22. Clark, R. P. 1997. Standards for safety cabinets. Nature 390:550.
23. Coia, J. E. 1998. Nosocomial and laboratory-acquired infection with Escherichia coli O157. J. Hosp. Infect. 40:107-413.
24. Collaco, R. E., X. Cao, and J. P. Trempe. 1999. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 238:397-405.
25. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
26. Curtiss, R. 1978. Biological containment and cloning vector transmissibility. J. Infect. Dis. 137:668-675.
27. Danelishvili, L., L. S. Young, and L. E. Bermudez. 2006. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a non-virulent mycobacterium. Microb. Drug Resist. 12:1-6.
28. Darquet, A. M., B. Cameron, P. Wils, D. Scherman, and J. Crouzet. 1997. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 12:1341-1349.
29. Debyser, Z. 2003. Biosafety of lentiviral vectors. Curr. Gene Ther. 3:517-525.
30. De Cock, B., and G. van Eetvelde. 2007. Biologische Veiligheid. Verkennende bio-incidentenanalyse in Vlaanderen. Report, Vlaamse milieumaatschappij, MIRA/2007/01. www.biorisico.UGent.be.
31. de Wind, N., B. P. Peeters, A. Zuderveld, A. L. Gielkens, A. J. Berns, and T. G. Kimman. 1994. Mutagenesis and characterization of a 41-kilobase-pair region of the pseudorabies virus genome: transcription map, search for virulence genes, and comparison with homologs of herpes simplex virus type 1. Virology 200:784-790.
32. Dietrich, G., A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H. Kaufmann, J. Hess, A. A. Szalay, and W. Goebel. 1998. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 16:181-185.
33. Dilts, D. A., I. Riesenfeld-Orn, J. P. Fulginiti, E. Ekwall, C. Granert, J. Nonenmacher, R. N. Brey, S. J. Cryz, K. Karlsson, K. Bergman, T. Thompson, B. Hu, A. H. Brückner, and A. A. Lindberg. 2000. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 18:1473-1484.
34. DiPetrillo, M. D., T. Tibbetts, H. Kleanthous, K. P. Killeen, and E. L. Hohmann. 1999. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18:449-459.
35. Reference deleted.
36. Emond, R. T., B. Evans, E. T. Bowen, and G. Lloyd. 1977. A case of Ebola virus infection. Br. Med. J. 2:541-544.
37. Enserink, M., and L. Du. 2004. SARS. China dumps CDC head, probes lab. Science 305:163.
38. Escarpe, P., N. Zayek, P. Chin, F. Borellini, R. Zufferey, G. Veres, and V. Kiermer. 2003. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol. Ther. 8:332-341.
39. Evans, M. R., D. K. Henderson, and J. E. Bennett. 1990. Potential for laboratory exposures to biohazardous agents found in blood. Am. J. Public Health 80:423-427.
40. Farson, D., R. McGuinness, T. Dull, K. Limoli, R. Lazar, S. Jalali, S. Reddy, R. Pennathur-Das, D. Broad, and M. Finer. 1999. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols. J. Gene Med. 1:195-209.
41. Fenner, F., D. A. Henderson, I. Arita, Z. Ježek, and I. D. Ladnyi. 1988. Small pox and its eradication. WHO, Geneva, Switzerland. http://whqlibdoc.who.int/smallpox/9241561106.pdf.
42. Feldmann, H., W. Slenczka, and H. D. Klenk. 1996. Emerging and reemerging of Filoviruses. Arch. Virol. Suppl. 11:77-100.
43. Feldmann, H., S. Jones, H. D. Klenk, and H. J. Schnittler. 2003. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3:677-685.
44. Flemming, D. O. 2000. Risk assessment of biological hazards, p. 57-64. In D. O. Flemming and D. L. Hunt (ed.), Biological safety: principles and practices, 3rd ed. ASM Press, Washington, DC.
45. Gandsman, E. J., H. G. Aaslestad, T. C. Ouimet, and W. D. Rupp. 1997. Sabia virus incident at Yale University. Am. Ind. Hyg. Assoc. J. 58:51-53.
46. Gershon, R. R., D. Vlahov, S. A. Felknor, D. Vesley, P. C. Johnson, G. L. Declos, and L. R. Murphy. 1995. Compliance with universal precautions among health care workers at three regional hospitals. Am. J. Infect. Control 23:225-236.
47. Gorbach, S. L. 1978. Recombinant DNA: an infectious disease perspective. J. Infect. Dis. 137:615-623.
48. Grimm, D., P. Staeheli, M. Hufbauer, I. Koerner, L. Martínez-Sobrido, A. Solórzano, A. García-Sastre, O. Haller, and G. Kochs. 2007. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl. Acad. Sci. USA 104:6806-6811.
49. Grist, N. R., and J. A. N. Emslie. 1991. Infections in British clinical laboratories, 1988-1989. J. Clin. Pathol. 44:667-669.
50. Gruner, E., E. Bernasconi, R. L. Galeazzi, D. Buhl, R. Heinzle, and D. Nadal. 1994. Brucellosis: an occupational hazard for medical laboratory personnel. Report of five cases. Infection 22:33-36.
51. Guibourdenche, M., J. P. Darchis, A. Boisivon, E. Collatz, and J. Y. Riou. 1994. Enzyme electrophoresis, sero- and subtyping, and outer membrane protein characterization of two Neisseria meningitidis strains involved in laboratory-acquired infections. J. Clin. Microbiol. 32:701-704.
52. Hanson, R. P., S. E. Sulkin, E. L. Beuscher, W. M. Hammon, R. W. McKinney, and T. H. Work. 1967. Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. Science 158:1283-1286.
53. Harding, A. L., and K. B. Byers. 2006. Epidemiology of laboratory-associated infections, p. 53-77. In D. O. Flemming and D. L. Hunt (ed.), Biological safety: principles and practices, 4th ed. ASM Press, Washington, DC.
54. Health and Safety Executive. 2007. Final report on potential breaches of biosecurity at the Pirbright site 2007. http://www.hse.gov.uk/news/ archive/07aug/finalreport.pdf.
55. Heidt, P. J. 1982. Bacteriological testing of a modified laminar flow microbiological safety cabinet. Antonie van Leeuwenhoek 48:373-381.
56. Heimeriks, K. 2007. Surveillance van arbeidsgerelateerde infectieziekten. Report LCI/CIb. RIVM, Bilthoven, The Netherlands.
57. Herwaldt, B. L. 2001. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev. 14:659-688.
58. Isaacs, S. N. 2004. Working safely with vaccinia virus: laboratory technique and the role of vaccinia vaccination. Methods Mol. Biol. 269:1-14.
59. Jackson, R. J., A. J. Ramsay, C. D. Christensen, S. Beaton, D. F. Hall, and I. A. Ramshaw. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:1205-1210.
60. Jones, L., S. Ristow, T. Yilma, and B. Moss. 1986. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 319:543.
61. Kahn, L. H. 2004. Biodefense research: can secrecy and safety coexist? Biosecur. Bioterror. 2:81-85.
62. Kaiser, J. 2007. Accidents spur a closer look at risks at biodefense labs. Science 317:1852-1854.
63. Kaiser, J. 2007. Lawmakers worry that lab expansion poses risks. Science 318:182.
64. Kao, A. S., D. A. Ashford, M. M. McNeil, N. G. Warren, and R. C. Good. 1997. Descriptive profile of tuberculin skin testing programs and laboratory-acquired tuberculosis infections in public health laboratories. J. Clin. Microbiol. 35:1847-1851.
65. Käppeli, O., and L. Auberson. 1997. The science and intricacy of environmental safety evaluations. Trends Biotechnol. 9:342-349.
66. Keatley, K. L. 2000. Controversy over genetically modified organisms: the governing laws and regulations. Qual. Assur. 8:33-36.
67. Kennedy, D. A., and C. H. Collins. 2000. Microbiological safety cabinets: selection, installation, testing, and use. Br. J. Biomed. Sci. 57:330-337.
68. Khan, S. A., R. Stratford, T. Wu, N. Mckelvie, T. Bellaby, Z. Hindle, K. A. Sinha, S. Eltze, P. Mastroeni, D. Pickard, G. Dougan, S. N. Chatfield, and F. R. Brennan. 2003. Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella pathogenicity island-2 (SPI-2) genes as vaccines and vectors. Vaccine 21:538-548.
69. Kimman, T. G., A. L. Gielkens, K. Glazenburg, L. Jacobs, M. C. de Jong, W. A. Mulder, and B. P. Peeters. 1995. Characterization of live pseudorabies virus vaccines. Dev. Biol. Stand. 84:89-96.
70. Knudsen, S., P. Saadbye, L. H. Hansen, A. Collier, B. L. Jacobsen, J. Schlundt, and O. H. Karlstrom. 1995. Development and testing of improved suicide functions for biological containment of bacteria. Appl. Environ. Microbiol. 61:985-991.
71. Kobasa, D., A. Takada, K. Shinya, M. Hatta, P. Halfmann, S. Theriault, H. Suzuki, H. Nishimura, K. Mitamura, N. Sugaya, T. Usui, T. Murata, Y. Maeda, S. Watanabe, M. Suresh, T. Suzuki, Y. Suzuki, H. Feldmann, and Y. Kawaoka. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707.
72. Kochi, S. K., K. P. Killeen, and U. S. Ryan. 2003. Advances in the development of bacterial vector technology. Expert Rev. Vaccines 2:31-43.
73. Kost, T. A., J. P. Condreay, and C. A. Mickelson. 2000. Biosafety and viral gene transfer factors, p. 579-597. In D. O. Flemming and D. L. Hunt (ed.), Biological safety: principles and practices, 3rd ed. ASM Press, Washington, DC.
74. Kristoffersen, P., G. B. Jensen, K. Gerdes, and J. Piskur. 2000. Bacterial toxin-antitoxin gene system as containment control in yeast cells. Appl. Environ. Microbiol. 66:5524-5526.
75. Kruse, R. H. 1962. Potential aerogenic laboratory hazards of Cuccidioides immitis. Am. J. Clin. Pathol. 37:150-158.
76. Laquerre, S., W. F. Goins, S. Moriuchi, T. J. Oligino, D. M. Krisky, P. Marconi, M. K. Soares, J. B. Cohen, J. C. Glorioso, and D. J. Fink. 1999. Gene transfer tool: herpes simplex virus vectors, p. 173-208. In T. Friedmann (ed.), The development of gene therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
77. Leifer, E., D. J. Gocke, and H. Bourne. 1970. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19:677-679.
78. Lennartz, K., L. Mengli, M. Flasshove, T. Moritz, and U. Kirstein. 2005. Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet. Cytometry 66A:119-127.
79. Lewis, F. M., E. Chernak, E. Goldman, Y. Li, K. Karem, I. K. Damon, R. Henkel, C. Newbern, P. Ross, and C. C. Johnson. 2006. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg. Infect. Dis. 12:134-137.
80. Li, L., J. Gu, X. Shi, E. Gong, X. Li, H. Shao, X. Shi, H. Jiang, X. Gao, D. Cheng, L. Guo, H. Wang, X. Shi, P. Wang, Q. Zhang, and B. Shen. 2005. Biosafety level 3 laboratory for autopsies of patients with severe acute respiratory syndrome: principles, practices, and prospects. Clin. Infect. Dis. 41:815-821.
81. Lim, P. L., A. Kurup, G. Gopalakrishna, K. P. Chan, C. W. Wong, L. C. Ng, S. Y. Se-Thoe, L. Oon, X. Bai, L. W. Stanton, Y. Ruan, L. D. Miller, V. B. Vega, L. James, P. L. Ooi, C. S. Kai, S. J. Olsen, B. Ang, and Y. S. Leo. 2004. Laboratory-acquired severe acute respiratory syndrome. N. Engl. J. Med. 350:1740-1745.
82. Lim, W., and D. N. C. Tsang. 2006. Laboratory containment of SARS virus. Ann. Acad. Med. Singapore 35:354-360.
83. Lisieux, T., M. Coimbra, E. S. Nassar, M. N. Burattini, L. T. de Souza, I. Ferreira, I. M. Rocco, A. P. da Rosa, P. F. Vasconcelos, F. P. Pinheiro, et al. 1994. New arenavirus isolated in Brazil. Lancet 343:391-392.
84. Loeb, M., I. Zando, M. C. Orvidas, A. Bialachowski, D. Groves, and J. Mahoney. 2003. Laboratory-acquired vaccinia infection. Can. Commun. Dis. Rep. 29:134-136.
85. Low, K. B., M. Ittensohn, T. Le, J. Platt, S. Sodi, M. Amoss, O. Ash, E. Carmichael, A. Chakraborty, J. Fischer, S. L. Lin, X. Luo, S. I. MillerI, L. Zheng, I. King, J. M. Pawelek, and D. Bermudes. 1999. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 17:37-41.
86. Lucero, N. E., and F. Sineriz. 2005. The Argentine experience in enhancing biosafety through good laboratory practices. Asian Biotechnol. Dev. Rev. 8:99-120.
87. Macher, J. M., and M. W. First. 1984. Effects of airflow rates and operator activity on containment of bacterial aerosols in a class II safety cabinet. Appl. Environ. Microbiol. 48:481-485.
88. Marshall, B. M., H. Shin-Kim, D. Perlov, and S. B. Levy. 1999. Release of bacteria during the purge cycles of steam-jacketed sterilizers. Br. J. Biomed. Sci. 56:247-252.
89. Memish, Z. A., and M. W. Mah. 2001. Brucellosis in laboratory workers at a Saudi Arabian hospital. Am. J. Infect. Control 29:48-52.
90. Mempel, M., G. Isa, N. Klugbauer, H. Meyer, G. Wildi, J. Ring, F. Hofmann, and H. Hofmann. 2003. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulatiug construct. J. Investig. Dermatol. 120:356-358.
91. Michael, A., R. Stratford, S. Khan, A. Dalgleish, and H. Pandha. 2004. Novel strains of Salmonella typhimurium as potential vectors for gene delivery. FEMS Microbiol. Lett. 238:345-351.
92. Miller, C. D., J. R. Songer, and J. F. Sullivan. 1987. A twenty-five year review of laboratory-acquired human infections at the National Animal Disease Center. Am. Ind. Hyg. Assoc. J. 48:271-275.
93. Mortland, K. K., and D. B. Mortland. 2003. Biosafety considerations in laboratory design. Clinical leadership and management. 17:175-177.
94. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Poc. Natl. Acad. Sci. USA 93:11341-11348.
95. Moussatché, N., M. Tuyama, S. E. Kato, A. P. Castro, B. Njaine, R. H. Peralta, J. M. Peralta, C. R. Damaso, and P. F. Barroso. 2003. Accidental infection of laboratory worker with vaccinia virus. Emerg. Infect. Dis. 9:724-726.
96. Munro, K., J. Lanser, and R. Flower. 1999. A comparative study of methods to validate formaldehyde decontamination of biological safety cabinets. Appl. Environ. Microbiol. 65:873-876.
97. Nahrstedt, H., J. Waldeck, M. Grone, R. Eichstadt, J. Feesche, and F. Meinhardt. 2005. Strain development in Bacillus licheniformis: construction of biologically contained mutants deficient in sporulation and DNA repair. J. Biotechnol. 119:245-254.
98. Nalca, A., A. W. Rimoin, S. Bavari, and C. A. Whitehouse. 2005. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin. Infect. Dis. 41:1765-1771.
99. Nelson, C. H. 2001. Risk perception, behavior, and consumer response to genetically modified organisms. Toward understanding American and European public reaction. Am. Behav. Sci. 44:1371-1388.
100. Nikiforov, V. V., I. U. I. Turovskiǐ, P. P. Kalinin, L. A. Akinfeeva, L. R. Katkova, V. S. Barmin, E. I. Riabchikova, N. I. Popkova, A. M. Shestopalov, V. P. Nazarov, et al. 1994. A case of a laboratory infection with Marburg fever. Zh. Mikrobiol. Epidemiol. Immunobiol. 3:104-106. (In Russian.)
101. Normile, D. 2003. SARS experts want labs to improve safety practices. Science 302:31.
102. Normile, D. 2004. Infectious diseases. Second lab accident fuels fears about SARS. Science 303:26.
103. Normile, D. 2004. Severe acute respiratory syndrome: lab accidents prompt calls for new containment program. Science 304:1223-1225.
104. Noviello, S., R. Gallo, M. Kelly, R. J. Limberger, K. DeAngelis, L. Cain, B. Wallace, and N. Dumas. 2004. Laboratory-acquired brucellosis. Emerg. Infect. Dis. 10:1848-1850.
105. Nulens, E., and A. Voss. 2002. Laboratory diagnosis and biosafety issues of biological warfare agents. Clin. Microbiol. Infect. 8:455-466.
106. Openshaw, P. J., W. H. Alwan, A. H. Cherrie, and F. M. Record. 1991. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338:459.
107. O'Reilly, D. R., L. K. Mileer, and V. A. Luckow. 1994. Baculovirus expression vectors: a laboratory manual. Oxford University Press, New York, NY.
108. Osborne, R., T. Durkin, H. Shannon, E. Dornan, and C. Hughes. 1999. Performance of open fronted microbiological safety cabinets: the value of operator protection tests during routine servicing. J. Appl. Microbiol. 86:962-970.
109. Paoletti, E. 1996. Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:349-353.
110. Peeters, B., A. Bouma, T. de Bruin, R. Moormann, A. Gielkens, and T. Kimman. 1994. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. Vaccine 12:375-380.
111. Perfetto, S. P., D. R. Ambrozak, R. A. Koup, and M. Roederer. 2003. Measuring containment of viable infectious cell sorting in high-velocity cell sorters. Cytometry 52A:122-130.
112. Perfetto, S. P., D. R. Ambrozak, M. Roederer, and R. A. Koup. 2004. Viable infectious cell sorting in a BSL-3 facility. Methods Mol. Biol. 263:419-424.
113. Phillips, G. B. 1965. Microbiological hazards in the laboratory. I. Control. J. Chem. Educ. 42A:43-48.
114. Phillips, G. B., and R. S. Runkle. 1967. Laboratory design for microbiological safety. Appl. Microbiol. 15:378-389.
115. Pike, R. M. 1976. Laboratory-associated infections: summary and analysis of 3921 cases. Health Lab. Sci. 13:105-114.
116. Pike, R. M. 1978. Past and present hazards of working with infectious agents. Arch. Pathol. Lab. Med. 102:333-336.
117. Pike, R. M. 1979. Laboratory-associated infections: incidence, fatalities, causes, and prevention. Annu. Rev. Microbiol. 33:41-66.
118. Richmond, J. Y., R. C. Knudsen, and R. C. Good. 1996. Biosafety in the clinical mycobacteriology laboratory. Clin. Lab. Med. 3:527-550.
119. Romano, G., C. Pacilio, and A. Giordano. 1999. Gene transfer technology in therapy: current applications and future goals. Stem Cells 17:191-202.
120. Rusnak, J. M., M. G. Kortepeper, R. J. Hawley, A. O. Anderson, E. Boudreau, and E. Eitzen. 2004. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecur. Bioterror. 2:281-293.
121. Samulski, R. J., M. Sally, and N. Muzyczka. 1999. Adeno-associated viral vectors, p. 131-172. In T. Friedmann (ed.). The development of gene therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
122. Sargent, E. V., and F. Gallo. 2003. Use of personal protective equipment for respiratory protection. ILAR J. 44:52-56.
123. Sawyer, J., A. Bennet, V. Haines, E. Elton, K. Crago, and S. Speight. 2007. The effect of microbiological containment systems on dexterity. J. Occup. Environ. Hyg. 4:166-173.
124. Schellekens, H. 2001. Veilig werken met microorganismen, parasieten en cellen in laboratoria en andere werkruimtes. Nederlandse Vereniging voor Microbiologie, Bilthoven, The Netherlands.
125. Schmid, I., A. Kunkl, and J. K. Nicholson. 1999. Biosafety considerations for flow cytometric analysis of human immunodeficiency virus-infected samples. Cytometry 38:195-200.
126. Schmid, I., S. Merlin, and S. P. Perfetto. 2003. Biosafety concerns for shared flow cytometry core facilities. Cytometry A 56:113-119.
127. Schmid, I., C. Lambert, D. Ambrozak, G. E. Marti, D. M. Moss, S. P. Perfetto, and the International Society of Analytical Cytology. 2007. International Society for Analytical Cytology biosafety standard for sorting of unfixed cells. Cytometry A 71:414-437.
128. Schou, S., and A. K. Hansen. 2000. Marburg and Ebola virus infections in laboratory non-human primates: a literature review. Comp. Med. 50:108-123.
129. Schweder, T., I. Schmidt, H. Herrmann, P. Neubauer, M. Hecker, and K. Hofmann. 1992. An expression vector system providing plasmid stability and conditional suicide of plasmid-containing cells. Appl. Microbiol. Biotechnol. 38:91-93.
130. Seidler, A., A. Nienhaus, and R. Driel. 2005. Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas. Respiration 72:431-446.
131. Sejvar, J. J., D. Johnson, T. Popovic, J. M. Miller, F. Downes, P. Somsel, R. Weyant, D. S. Stephens, B. A. Perkins, and N. E. Rosenstein. 2005. Assessing the risk of laboratory-acquired meningococcal disease. J. Clin. Microbiol. 43:4811-4914.
132. Sewell, D. L. 1995. Laboratory-associated infections and biosafety. Clin. Microbiol. Rev. 8:389-405.
133. Smith, C. E., D. I. Simpson, E. T. Bowen, and I. Zlotnik. 1967. Fatal human disease from Vervet monkeys. Lancet ii:119-1121.
134. Sorensen, T. U., G. J. Gram, S. D. Nielsen, and J. E. Hansen. 1999. Safe sorting of GFP-transduced live cells for subsequent culture using a modified FACS vantage. Cytometry 37:284-290.
135. Spina, N., S. Zansky, N. Dumas, and S. Kondracki. 2005. Four laboratory-associated cases of infection with Escherichia coli O157:H7. J. Clin. Microbiol. 43:2938-2939.
136. Srinivasan, A., C. N. Kraus, D. DeShazer, P. M. Becker, J. D. Dick, L. Spacek, J. G. Bartlett, W. R. Byrne, and D. L. Thomas. 2001. Glanders in a military research microbiologist. N. Engl. J. Med. 345:256-258.
137. Steidler, L., S. Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B. Goddeeris, E. Cox, J. P. Remon, and E. Remaut. 2003. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21:785-789.
138. Steidler, L. 2004. Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology? Expert Opin. Biol. Ther. 4:439-441.
139. Sulkin, S. E., and R. M. Pike. 1951. Laboratory infections. Science 114:3.
140. Sulkin, S. E., and R. M. Pike. 1951. Survey of laboratory-acquired infections. Am. J. Public Health Nations Health 41:769-781.
141. Swanepoel, R. 2001. Marburg hemorrhagic fever, 1967 to the present. ProMED-mail, 7 February 2001. 20010207.0242. http://www.promedmail.org. Accessed 22 September 2007.
142. Tacket, C. O., S. M. Kelly, F. Schodel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, and R. Curtiss. 1997. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65:3381-3385.
143. Thompson, R. J., H. G. Bouwer, D. A. Portnoy, and F. R. Frankel. 1998. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect. Immun. 66:3552-3561.
144. Tumpey, T. M., C. F. Basler, P. V. Aguilar, H. Zeng, A. Solórzano, D. E. Swayne, N. J. Cox, J. M. Katz, J. K. Taubenberger, P. Palese, and A. García-Sastre. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77-80.
145. Vaquero, M., P. Gomez, M. Romero, and M. J. Casal. 2003. Investigation of biological risk in mycobacteriology laboratories: a multicentre study. Int. J. Tuberc. Lung Dis. 7:879-885.
146. VROM. 2004. Integrale versie van de Regeling genetisch gemodificeerde Organismen en het Besluit genetische gemodificeerde organismen. Ministerie voor Volksgezondheid, Ruimtelijke Ordening en Milieu, Den Haag, The Netherlands.
147. Walker, D., and D. Campbell. 1999. A survey of infections in United Kingdom laboratories, 1994-1995. J. Clin. Pathol. 52:415-418.
148. Wedum, A. G. 1953. Bacteriological safety. Am. J. Public Health Nations Health 43:1428-1437.
149. Wedum, A. G., E. Hanel, G. Briggs Phillips, and O. T Miller. 1956. Laboratory design for study of infectious disease. Am. J. Public Health Nations Health 46:1102-1113.
150. Wedum, A. G. 1961. Control of laboratory airborne infection. Bacteriol. Rev. 25:210-216.
151. Wedum, A. G. 1964. Laboratory safety in research with infectious aerosols. Public Health Rep. 79:619-633.
152. Wedum, A. G. 1964. Airborne infection in the laboratory. Am. J. Public Health Nations Health 54:1669-1673.
153. WHO. 2004. Laboratory biosafety manual, 3rd ed. World Health Organization, Geneva, Switzerland.
154. Williams, N. R., and B. M. Cooper. 1993. Counselling of workers handling vaccinia virus. Occup. Med. (London) 43:125-127.
155. Williams-Smith, H. 1978. Is it safe to use Escherichia coli in recombinant DNA experiments? J. Infect. Dis. 137:655-660.
156. Willshaw, G. A., J. Thirlwell, A. P. Jones, S. Parry, R. L. Salmon, and M. Hickey. 1994. Vero cytotoxin-producing Escherichia coli O157 in beefburgers linked to an outbreak of diarrhoea, haemorrhagic colitis and haemolytic uraemic syndrome in Britain. Lett. Appl. Microbiol. 19:304-307.
157. Wilson, D. E., and L. C. Chosewood, ed. 2007. Biosafety in microbiological and biomedical laboratories, 5th ed. CDC and NIH, Washington, DC. www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.
158. Reference deleted.
159. Wlodaver, C. G., G. J. Palumbo, and J. L. Waner. 2004. Laboratory-acquired vaccinia infection. J. Clin. Virol. 29:167-170.
160. Yagupsky, P., N. Peled, K. Riesenberg, and M. Banai. 2000. Exposure of hospital personnel to Brucella melitensis and occurrence of laboratory-acquired disease in an endemic area. Scand. J. Infect. Dis. 32:31-35.
161. Yamashita, G. M., T. Misawa, T. Komori, K. Okuzumi, and T. Takahashi. 2007. Current biosafety in clinical laboratories in Japan: report of questionnaire data obtained from clinical laboratory personnel in Japan. Kanesnhogaku Zasshi 81:39-44.